Potential impact of a Moraxella catarrhalis vaccine in COPD |
| |
| Affiliation: | 1. Clinical and Translational Research Center, University at Buffalo, The State University of New York, 875 Ellicott Street, Buffalo, NY 14203, USA;2. Division of Infectious Diseases, Department of Medicine, University at Buffalo, The State University of New York, 875 Ellicott Street, Buffalo, NY 14203, USA;3. Department of Microbiology, University at Buffalo, The State University of New York, 875 Ellicott Street, Buffalo, NY 14203, USA;1. Professor Emeritus of Pediatrics, Università degli Studi di Milano, Milano, Italy;2. Pediatric Clinic, Department of Surgical and Biomedical Sciences, Università degli Studi di Perugia, Perugia, Italy;1. Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany;2. Boehringer Ingelheim Pharma GmbH and Co KG, Ingelheim, Germany;3. Department of Sports Medicine, University of Tübingen, Tübingen, Germany;4. Department of Respiratory Medicine, Maastricht University Medical Center, Maastricht, Netherlands;5. Universitat de Barcelona, Hospital Clínic IDIBAPS-CIBERES, Barcelona, Spain;6. Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-Universität Marburg, German Center for Lung Research, Marburg, Germany;7. Department of Metabolic Medicine, University of Modena & Reggio Emilia, Modena, NOCSAE, AUSL Modena, Baggiovara, Italy;8. Aix-Marseille Université, Department of Respiratory Diseases and CIC Nord, AP-HM-Hôpital Nord, Marseille, France;9. University of Southern Denmark, Odense, Denmark;10. Department of Biostatistics and Data Sciences, Boehringer Ingelheim, Bracknell, UK;11. Institute of Ageing and Chronic Disease, Aintree University Hospital, Liverpool, UK;1. Division of Paediatrics, University of Western Australia, Western Australia, Australia;2. Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Western Australia, Australia;3. Papua New Guinea Institute of Medical Research, Goroka, Eastern Highlands Province, Papua New Guinea;4. Centre for Child Health Research, University of Western Australia, Perth, Australia;5. School of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Western Australia, Perth, Australia;1. Department of Infectious Diseases, Keio University School of Medicine, Shinjuku, Japan;2. The Drug-Resistant Pathogen Surveillance Group in Pediatric Infectious Disease, Japan;3. Department of Pediatrics, Fuji Heavy Industries Health Insurance Society Ota Memorial Hospital, Ota, Japan;4. Department of Pediatrics, Saitama Sekishinkai Hospital, Sayama, Japan;5. The Kitasato Institute, Kitasato University Research Center for Anti-infectious Drugs, Minato, Japan;6. The Kitasato Institute, Kitasato University Research Organization for Infection Control Sciences, Minato, Japan |
| |
| Abstract: | Moraxella catarrhalis is the second most common cause of exacerbations in adults with COPD, resulting in enormous morbidity and mortality in this clinical setting. Vaccine development for M. catarrhalis has lagged behind the other two important causes of exacerbations in COPD, nontypeable Haemophilus influenzae and Streptococcus pneumoniae. While no licensed vaccine is currently available for M. catarrhalis, several promising candidate vaccine antigens have been identified and characterized and are close to entering clinical trials. Key steps that are required to advance vaccines for M. catarrhalis along the translational pipeline include standardization of assay systems to assess candidate antigens, identification of a reliable correlate of protection and expansion of partnerships between industry, academia and government to overcome regulatory hurdles. A vaccine to prevent M. catarrhalis infections in COPD would have a major impact in reducing morbidity, mortality and healthcare costs in COPD. |
| |
| Keywords: | COPD Vaccine Chronic lung disease Airway pathogen |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
